Logo image of TLGT

Teligent Inc (TLGT) Stock Fundamental Analysis

NASDAQ:TLGT - Nasdaq -

0.1735  -0.03 (-13.85%)

After market: 0.1717 0 (-1.04%)

Fundamental Rating

2

TLGT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. TLGT may be in some trouble as it scores bad on both profitability and health. TLGT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TLGT had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -101.27%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -296.25%
PM (TTM) -197.78%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

There is no outstanding debt for TLGT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

TLGT has an Altman-Z score of -6.66. This is a bad value and indicates that TLGT is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -2.67 indicates that TLGT is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -2.67
Debt/FCF N/A
Altman-Z -6.66
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 4.10 indicates that TLGT has no problem at all paying its short term obligations.
TLGT has a Quick Ratio of 2.74. This indicates that TLGT is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 2.74

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.02% over the past year.
Looking at the last year, TLGT shows a very negative growth in Revenue. The Revenue has decreased by -16.53% in the last year.
The Revenue has been growing slightly by 0.47% on average over the past years.
EPS 1Y (TTM)27.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.91%
Revenue 1Y (TTM)-16.53%
Revenue growth 3Y-9.04%
Revenue growth 5Y0.47%
Sales Q2Q%-23.21%

3.2 Future

The Earnings Per Share is expected to grow by 17.63% on average over the next years. This is quite good.
TLGT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.27% yearly.
EPS Next Y131.61%
EPS Next 2Y65.35%
EPS Next 3Y24.17%
EPS Next 5Y17.63%
Revenue Next Year-16.85%
Revenue Next 2Y-16.02%
Revenue Next 3Y-0.47%
Revenue Next 5Y-0.27%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TLGT Yearly Revenue VS EstimatesTLGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TLGT Yearly EPS VS EstimatesTLGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 4 -4 -6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

TLGT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 0.04 indicates a rather cheap valuation of TLGT.
TLGT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.70.
Industry RankSector Rank
PE N/A
Fwd PE 0.04
TLGT Price Earnings VS Forward Price EarningsTLGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.85
TLGT Per share dataTLGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TLGT's earnings are expected to grow with 24.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.35%
EPS Next 3Y24.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLGT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Teligent Inc

NASDAQ:TLGT (10/15/2021, 8:08:54 PM)

After market: 0.1717 0 (-1.04%)

0.1735

-0.03 (-13.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/dmh
Inst Owners12.88%
Inst Owner Change-1.18%
Ins Owners0.36%
Ins Owner Change0%
Market Cap16.10M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.04
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -0.85
EPS(TTM)-7.24
EYN/A
EPS(NY)4.7
Fwd EY2706.29%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.5
BVpS-0.47
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.27%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -296.25%
PM (TTM) -197.78%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity -2.67
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 2.74
Altman-Z -6.66
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.91%
EPS Next Y131.61%
EPS Next 2Y65.35%
EPS Next 3Y24.17%
EPS Next 5Y17.63%
Revenue 1Y (TTM)-16.53%
Revenue growth 3Y-9.04%
Revenue growth 5Y0.47%
Sales Q2Q%-23.21%
Revenue Next Year-16.85%
Revenue Next 2Y-16.02%
Revenue Next 3Y-0.47%
Revenue Next 5Y-0.27%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A